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DBackground: Standard cryopreserved valved allografts (SCAs) are recognized as the benchmark for reconstruc-
tion of the right ventricular outflow tract (RVOT). However, SCAs frequently demonstrate early valve deterio-
ration and elicit an immune response. Decellularized cryopreserved valve allografts (SynerGraft, SG) are less
immunogenetic and may be more durable. This study analyzed our results of RVOT reconstruction using SGs
and compared it with the SCAs used during the same period.
Methods:We reviewed the outcome of all allografts (SG and SCA) that were implanted for RVOT reconstruc-
tion at a single center from 2000 to 2005. Echocardiographic data were reviewed to evaluate valve performance.
Conduit failure is defined as the need for conduit replacement or reintervention in either the catheterization lab-
oratory or operating room. Conduit dysfunction is defined as RVOT obstruction with peak echocardiographic
Doppler gradient greater than 40 mm Hg and/or grade III/IV or greater conduit valve regurgitation. Data
were compared using the Wilcoxon rank sum and Fisher’s exact test.
Results: From January 2000 to April 2005, 100 patients (mean age 18.6  16.8 years) received SG (n ¼ 39) or
SCA (n ¼ 61) conduits. The 2 retrospective nonrandomized cohorts were similar with respect to age, gender,
weight, conduit indication, bypass and crossclamp time, and conduit size. Follow-up time was not significant
between the 2 groups (SG, 5.7  2.5 years vs SCA, 5.8  2.8 years; P ¼ .83). Early and late mortality were
similar (SG, 13%; SCA, 10%; P ¼ .75). No death was graft related. Freedom from dysfunction was superior
with SG (SG, 74%, vs SCA, 52%; P ¼ .05). Freedom from failure was also better in patients with SG (SG,
87%, vs SCA, 68%; P ¼ .05). Freedom from explantation and more than moderate pulmonary insufficiency
were significantly better for SG patients (SG, 92% and 90%, vs SCA, 78% and 68%; P ¼ .02).
Conclusions: This study suggests that the midterm performance of SGs may be superior to that of SCAs.
Decellularization of the cryopreserved allografts may provide a more durable option for patients who need
RVOT reconstruction. Further long-term follow-up is needed to see whether this decellularization process im-
proves long-term allograft durability. (J Thorac Cardiovasc Surg 2012;143:543-9)Right ventricular–pulmonary artery (RV-PA) conduits have
made possible the repair ofmany complex congenital cardiac
lesions involving atresia or hypoplasia of the RVoutflow tract
(RVOT). These fundamental diagnoses include truncus
arteriosus, pulmonary atresia with ventricular septal defect,
severe tetralogy of Fallot, transposition with ventricular sep-
tal defect andpulmonary atresia, and various formsof double-
outlet RV. Conduits have also made possible the pulmonary
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The Journal of Thoracic and CaNumerous valved conduits have been introduced since an
aortic allograft was first used clinically in the mid-1960s.2-5
Conduit types include bioprostheses in Dacron tubes,
stented bovine or porcine xenografts in pericardial tubes,
glutaraldehyde-fixed aortic or pulmonary roots, nonvalved
tissue or prosthetic conduits, and aortic and pulmonary
allografts.
The standard cryopreserved allograft (SCA) subse-
quently became the conduit of choice in the United States
for RVOT reconstruction in the mid-1980s. Development
of cryopreservation techniques has improved the availabil-
ity and durability of allografts considerably, resulting in in-
creasing use in clinical practice. Early results with SCAs for
reconstruction of the RVOT in congenital heart disease have
been good, but there are few long-term studies reporting
allograft dysfunction and failure.4-6
Many SCAs are prone to shrinkage, leading to conduit ste-
nosis and the development of significant valve regurgitation
within months of insertion, especially when implanted as ex-
tracardiac conduits.5 Inmost patients receiving a transplanted
allograft valve, humoral antibodies develop against humanrdiovascular Surgery c Volume 143, Number 3 543
Abbreviations and Acronyms
PA ¼ pulmonary artery
PRA ¼ panel reactive antibody
RVOT ¼ right ventricular outflow tract
RV ¼ right ventricle (ventricular)
SCA ¼ standard cryopreserved allograft
SG ¼ SynerGraft
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Dleukocyte antigen that are specific to the transplanted tissue,7
and host antigen recognition and antibody development may
be linked to early-onset tissue calcification and structural
valve deterioration.8-10 To improve these shortcomings, the
SynerGraft (SG; CryoLife, Inc, Kennesaw, Ga) process
decellularizes an allograft, leaving only connective tissue,
which then may become repopulated with host cells.10
Similar to the SCA, SG allografts do not need anticoagu-
lation and have excellent handling characteristics but may
have lower immunogenicity and be more durable. This
study analyzed our results of RVOT reconstruction using
SGs and compared them with results of the SCAs used dur-
ing the same period.PATIENTS AND METHODS
Study Patients
Between June 2000 and July 2005, 39 patients had implantation of a de-
cellularized cryopreserved valve allograft (SynerGraft, SG; CryoLife) as
a valved conduit for establishing continuity between the RV and PA at
the Children’s Hospital of Illinois, OSF Saint Francis Medical Center at
Peoria. Sixty-one contemporary controls were included, who received
standard cryopreserved pulmonary allografts (SCAs) during the same
time period. The choice of conduit was made preoperatively or in the op-
erating room by the surgeon on the basis of availability of allografts without
randomization. This retrospective study was performed after the institu-
tional review board approval was obtained.
All allografts were obtained from Cryolife, Inc (Marietta, Ga). No pa-
tient received a prosthesis that was undersized from a larger allograft.
Blood group matching could not be accommodated owing to allograft
availability. Conduit size was determined according to the calculated
Z-value for each implanted valve using the valve diameter compared
with the normal value. Our goal was to insert a conduit with a Z-score of
þ1 toþ3.
Demographic information, cardiac anatomy, preoperative hemodynam-
ics, operative details, and postoperative outcomes were recorded retrospec-
tively from patient records. Transthoracic echocardiography was used to
evaluate conduit gradients and the degree of pulmonary insufficiency. Con-
duit stenosis was assessed by the measurement of peak velocity using
continuous-wave Doppler technique. Valve regurgitation was quantified
as trivial (grade 1), mild (grade 2, flow into the RV without flow reversal
in the conduit), moderate (grade 3, flow reversal in conduit), and severe
(grade 4, flow reversal in branch pulmonary arteries).
Graft dysfunction is considered to be present if the peak echocardio-
graphic Doppler gradient is greater than 40 mmHg by 2-dimensional echo-
cardiography at any level within the RVOT and/or grade 3 or 4 conduit
valve insufficiency. Conduit failure is defined as the need for intervention
in either the catheterization laboratory or operating room. Excluded are
catheter interventions for peripheral PA stenosis not involving the distal544 The Journal of Thoracic and Cardiovascular Surgconduit anastomosis. Indications for replacement of the homograft for con-
duit stenosis include a peak gradient greater than 40mmHg and diminished
RV function or RV pressures greater than 75% of systemic pressure. Indi-
cations for replacement for regurgitation include grade 3 or 4 insufficiency
and evidence of progressive RV dilation by either echocardiography or
magnetic resonance imaging.
The patient demographics are summarized in Table 1. There were no
significant differences in age, number of neonates, sex, weight, previous
surgery on the pulmonary valve, or preoperative diagnoses.
Surgical Technique
The standard approach includes median sternotomy, bicaval cardiopul-
monary bypass, left ventricular venting, and moderate hypothermia (28C-
32C). Intracardiac repair was performed during aortic crossclamping with
intermittent cold blood cardioplegia. Conduit insertion was most often per-
formed with the crossclamp removed and the heart beating during rewarm-
ing. All allografts conduits were continuously agitated for 5 minutes in four
500-mL normal saline baths to remove glutaraldehyde. When applicable,
the incision in the PAwas extended leftward onto the left PA to accommo-
date a larger prosthesis and to avoid conduit distortion by the ascending
aorta and the sternum. The outflow end of the allograft conduit was cut
as short as possible to position the conduit valve at the distal anastomosis
well to the left of the sternum. The proximal anastomosis was augmented
anteriorly using a hood of polytetrafluoroethylene as needed. Stenosis in
a branch PA was relieved most often by extension of the allograft onto
the branch PAs.
The operative variables are summarized in Table 2. Concomitant proce-
dures were not significantly different between the groups (SCA, 38/61,
62%, vs SG, 20/39, 51%; P ¼ .28) and consisted of closure of atrial and
ventricular septal defects, repair of tricuspid or mitral valves, patch en-
largement or reduction of the PAs, and autograft replacement of the aortic
valve (Ross procedure). The cardiopulmonary bypass time, cardiac ische-
mic times, and mean conduit size were similar.
Follow-up
All surviving patients were examined by serial transthoracic echocardi-
ography every 6 to 12 months. Follow-up echo studies were available in
100% of patients. For SGs, the mean follow-up was 5.7 2.5 years, rang-
ing from 3 months to 10 years. The mean follow-up for SCAs was not sig-
nificantly different at 5.8  2.8 years, ranging from 3 months to 10 years
(P ¼ .83). Early death was defined as death in the hospital or within 30
days of surgery. All other deaths were considered late.
Statistical Analysis
Data are presented as the mean  standard deviation. Continuous vari-
ables were analyzed with the Student t test and categorical variables using
the c2 test. Variables for the 2 cohorts were compared using the 2-tailed un-
paired t test. Kaplan-Meier curves were generated for actuarial survival,
freedom from conduit dysfunction, freedom from conduit failure, and
freedom from conduit explantation. End points were time of death, first di-
agnosis of conduit dysfunction or failure, interventional or surgical reinter-
vention, and conduit replacement. The log–rank test was used to estimate
the statistical difference between the 2 types of conduits.RESULTS
Mortality
There were 3 early deaths, 2 deaths in the SCA group and
1 death in SG group. A 2-weeks-old neonate with critical
aortic stenosis and aortic insufficiency underwent Ross-
Konno repair employing a 15-mm SCA for RVOT recon-
struction and resection of endocardial fibroelastosis. Thisery c March 2012
TABLE 1. Demographics
SG SCA P value
Age (mean, range) 19.2  17.2 (1 w–72 y) 19.4  16.2 (1w–55 y) .96
Infants (<1 year) 6 (15%) 17 (28%) .11
Weight (mean, range; kg) 54.7  40.4 (2.8-167) 51.7  34.0 (2.5-140) .68
Gender (M/F) 25/14 33/28 .22
Preoperative diagnosis
AS (Ross procedure) 16* (41%) 21* (34%) .53
Tetralogy of Fallot 8 (21%) 15 (25%) .81
PA/VSD 7 (18%) 9 (15%) .78
Truncus arteriosus 4 (10%) 3 (5%) .43
TGA 2 (5%) 7 (11%) .48
Other 2 (5%) 6 (10%) .48
Previous operation on PV 20 (51%) 27 (44%) .32
SG, SynerGraft; SCA, standard cryopreserved allograft;M, male; F, female; AS, aortic stenosis; PA, pulmonary atresia; VSD, ventricular septal defect; TGA, transposition of the
great arteries; PV, pulmonary valve. *Twelve patients (SG group) and 18 patients (SCA group) underwent the Ross procedure; 4 patients (SG group) and 3 patients (SCA group)
underwent redo conduit replacement after the Ross procedure.
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Dpatient died 7 days postoperatively of sepsis and multiorgan
system failure while receiving extracorporeal membrane
oxygenation. The second death occurred in a 2-month-old
neonate with transposition of great arteries, double-outlet
RV, pulmonary stenosis, and ventricular septal defect who
underwent Rastelli repair with insertion of a 10-mm SCA.
Twenty days later severe pulmonary regurgitation devel-
oped and the patient underwent redo surgery with replace-
ment of the RV-PA conduit with a 12-mm Hancock
xenograft (Medtronic, Inc, Minneapolis, Minn). The patient
died on the third postoperative day of low cardiac output.
The final death occurred in a 4-year-old patient with pulmo-
nary atresia and ventricular septal defect who previously
underwent RV-PA conduit insertion 2 times (SCA and
Shelhigh conduits [Shelhigh, Inc, Union, NJ]). This patient
underwent Rastelli-type repair with implantation of
a 16-mm SG and died 1 week postoperatively of sepsis
and multiorgan failure.
There were 4 SG and 4 SCA late deaths (SG, 4/38, 11%,
vs SCA, 4/59, 7%; P ¼ .51). No death was attributed toTABLE 2. Operative variables
SG SCA P value
Additional cardiac procedures 20 (51%) 38 (62%) .28
Pulmonary autograft 12 18
PA branch arterioplasty 3 10
TV repair 2 6
ARR 2 2
IAA repair 1 1
CAVC repair 0 1
CPB (min) 175  103 181  68 .76
Aortic crossclamping time (min) 95  62 104  68 .50
Diameter of conduit (min, mm) 21.0  4.2 20.6  6.2 .69
Range (mm) 10-27 8-28
SG, SynerGraft; SCA, standard cryopreserved allograft; PA, pulmonary artery; TV, tri-
cuspid valve; ARR, aortic root replacement; IAA, interrupted aortic arch; CAVC, com-
plete atrioventricular canal; CPB, cardiopulmonary bypass.
The Journal of Thoracic and Castructural failure of the conduit. The actuarial survival in-
cluding hospital deaths for SG and SCAs at 5 (SG, 92%;
SCA, 89%) and 10 years (SG, 90%; SCA, 87%) was sim-
ilar for both groups (P ¼ .75) (Figure 1). The causes of late
deaths were low-output cardiac failure in patients with con-
genital noncardiac and cardiac anomalies (n ¼ 3), pneumo-
nia (n ¼ 2), noncardiac (n ¼ 2), and unknown (n ¼ 1).Freedom From Conduit Dysfunction
Among the 97 hospital survivors, 38 patients (SG, 10/38,
26%; SCA, 28/59, 52%) had evidence of significant
conduit dysfunction at the most recent follow-up or before
conduit replacement. The mode of dysfunction was charac-
terized as follows: stenosis with regurgitation in 22 patients
and stenosis or insufficiency alone in 10 and 6 patients, re-
spectively. Freedom from conduit dysfunction was signifi-
cantly worse in the SCA group (69% and 48% at 5 and
10 years, respectively) as compared with the SG group
(82% and 74% at 5 and 10 years, respectively; P ¼ .05)
(Figure 2).Freedom From Conduit Failure
At latest follow-up, 5 (13%) patients in the SG group ex-
hibited conduit failure secondary to stenosis and/or valve
dysfunction: 3 patients, explantation; 1 patient, percutane-
ous intervention; and 1 patient for both. The mean time to
reoperation in the SG group was 3.4  3.1 years (range,
9 months to 8 years). Percutaneous interventions were
required in 2 patients (balloon dilatation, 1 patient; stent
implantation, 1 patient); of these, 1 patient required conduit
explantation at 2 years after intervention.
Conduit failure was observed in 19 (33%) of 58 SCA pa-
tients (all surgical interventions). All surgical procedures
were explants. The mean time to reoperation for SCA was
3.4 2.8 years (range, 2 months to 9 years) and was not sig-
nificantly different from the SG group (P ¼ .96). At 5 andrdiovascular Surgery c Volume 143, Number 3 545
FIGURE 1. Kaplan-Meier estimated 10-year survival, including hospital
mortality. SG, SynerGraft; SCA, standard cryopreserved allograft.
FIGURE 3. Kaplan-Meier estimated 10-year freedom from conduit fail-
ure. SG, SynerGraft; SCA, standard cryopreserved allograft.
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ure was significantly higher in the SG group (90% and
87%; P ¼ .05; Figure 3). Freedom from explantation at 5
and 10 years was also significantly higher in the SG group
(92% and 90%; P¼ .02; Figure 4). The freedom from con-
duit failure was significantly higher in the SCA group for
patients with small conduits (19 mm; SCA 13% vs SG
64%; P ¼ .01) but not significant different for patients
with bigger conduits (20 mm; SCA 86% vs SG 93%;
P ¼ .23).
Conduit Retention and Function at Last Follow-up
Among the 89 late survivors (SG, 34/39, 87%, vs SCA,
55/61, 90%; P¼ .75), 65 patients retained their initial con-
duit at last follow-up (SG, 29/34, 85%, vs SCA, 36/55,
66%; P ¼ .05). In the SG group, pulmonary regurgitation
was trivial in 13 (45%) patients, mild in 13 (45%), and
moderate in 3 (10%) patients. Two patients had transcon-
duit gradients above 40 mm Hg (58 and 64 mm Hg). Con-
duit regurgitation among the 36 SCA patients was trivial
in 16 (44%), mild in 15 (42%), and moderate in 5 (14%)
patients. At latest follow-up, 4 (11%) patients in the SCA
group were being followed up with a transconduit gradientFIGURE 2. Kaplan-Meier estimated 10-year freedom from conduit dys-
function. SG, SynerGraft; SCA, standard cryopreserved allograft.
546 The Journal of Thoracic and Cardiovascular Surgabove 40 mm Hg (41, 49, 52, and 64 mmHg), including
1 patient with moderate pulmonary regurgitation.
Conduit Outcome in Patients Less Than 1Year of Age
We also compared the performance of conduits inserted
primarily in patients less than 1 year of age (SG, n ¼ 6;
SCA, n ¼ 17). Survival was 67% in the SG group and
71% in the SCA group (P ¼ .85). Freedom from explanta-
tion (SG 67% vs SCA 25%; P¼ .10) and failure (SG 50%
vs SCA 25%; P ¼ .27) trended lower in the SG cohort but
did not reach statistical significance. Freedom from conduit
dysfunction also trended lower in the SG cohort (SG 50%
vs SCA 19%; P ¼ .14).
COMMENT
Reconstructing RV-PA continuity using valved conduits
is an essential component in the treatment of many patients
with congenital heart disease. The valved allograft first re-
ported in the late 1960s has been the principal conduit
used in the United States since the mid-1980s. However,
midterm and long-term follow-up studies have clearly dem-
onstrated conduit obstruction and early valve insuffi-
ciency.2-4 In the majority of reports, all patients haveFIGURE 4. Kaplan-Meier estimated 10-year freedom from conduit ex-
plantation. SG, SynerGraft; SCA, standard cryopreserved allograft.
ery c March 2012
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Additionally, virtually all allografts calcify, but the rate of
calcification appears significantly greater in aortic
allografts, perhaps because of high elastin tissue content
within the aortic conduit wall.5 Accelerated degeneration
has been observed for aortic and pulmonary allograft con-
duits implanted in patients less than 1 year of age, perhaps
owing to host immunologic response to viable endothelial
cells within some SCA conduits.4-6
In addition, there is growing concern over donor-specific
cellular responses and elevated levels of tissue-specific an-
tibodies found in allograft valve recipients. Host antigen
recognition and antibody development may be linked to
early-onset tissue calcification and structural valve deterio-
ration.8,10,11 High panel reactive antibody (PRA) levels may
decrease the number of potential donors for those patients
who progress to a need for transplantation.10 Vogt and col-
leagues12 identified cellular rejection in the wall of allograft
material explanted from the RVOT of children. These in-
flammatory cells were predominantly T lymphocytes. Ra-
jani, Mee, and Ratliff9 identified cellular rejection in the
wall of allograft material explanted from the RVOT of
children, and the inflammatory cells identified were pre-
dominantly T lymphocytes. Shaddy and associates13 pro-
spectively measured the frequency of human leukocyte
antigen class I PRA in children undergoing open cardiac op-
erations with or without the implantation of allograft mate-
rial. They found that the PRA in patients receiving an SCA
increased within months of the operation, whereas PRA did
not change significantly in the control group. This immune
response is believed to have been caused by the SCA and
may be a contributory factor in the early degradation of
allograft function in some patients.
SG technology was developed as a decellularization pro-
cess for allograft tissue to reduce antigenicity. SG methods
result in native cell removal from the collagen tissue matrix
and the endothelium. Removal of cellular material may re-
duce or eliminate the immunologic response and leave
a functional vascular matrix that is available for autogenous
remodeling. Migration of the recipient-specific cells into
the matrix may eventually render the graft indistinguishable
from other endogenous tissue.14 Elkins and colleagues11
demonstrated the preservation of tissue strength, biome-
chanics, and valvular hydrodynamic function. The SG pul-
monary valve conduit was introduced into clinical use in
2000.
An in vitro comparison of decellularized human SGs with
SCAs revealed similar tissue mechanics and hemodynamic
performance. Hemodynamic testing revealed no differences
in valve gradient, valve closure volume, or diastolic regur-
gitation.11,15 Uniaxial tension loading demonstrated no
difference in conduit failure, leaflet failure, or suture
retention.15 Alfonso da Costa and colleagues16 demon-
strated that decellularized allografts are less antigenicThe Journal of Thoracic and Cathan standard cryopreserved allografts and exhibited nor-
mal hemodynamic performance in the right side of the cir-
culation up to 18 months after implantation. In contrast to
the SCAs, they could not detect any elevation in antibody
and PRA levels in 7 cases and only marginal elevation in
2 others.16
Tavakkol and associates15 demonstrated the superior
short-term durability of the SGs compared with SCAs
with respect to both stenosis and insufficiency. At longer
follow-up, Konuma and colleagues10 (from the same center)
found there were no significant differences between SGs
compared with SCA conduits with reference to stenosis
and valve insufficiency, although the overall degree of in-
sufficiency was higher in the SCAs (P ¼ .07). However,
when they analyzed the incidence of clinically important
(>3þ) insufficiency, they found a statistically significant ad-
vantage for the SG valve.10
Bechtel and colleagues17,18 evaluated a cohort of adult
patients who had undergone the Ross procedure for
performance of SGs in the RVOT in comparison with
SCAs. They demonstrated no difference with regard to
conduit regurgitation or reintervention, but surprisingly
SCAs were superior to SGs with regard to conduit
stenosis. Burch and colleagues19 concluded that decellular-
ized SGs have a nonsignificant trend toward lower peak
valve gradients and fewer reinterventions compared with
SCAs. Small valve sizes (18 mm) show a slight but signif-
icant improvement in peak gradient but no advantage in
valve insufficiency.
Brown and colleagues20 previously reported multicenter
results comparing SG and SCA RV-PA conduits in children
after a Ross procedure and demonstrated no difference in
RVOT gradient but did note a significant reduction of mid-
term regurgitation in the SG groups.20 This multicenter, ret-
rospective cohort study of 342 consecutive patients who
received the SG supported earlier evidence that the SG is
an appropriate graft for patients requiring pulmonary valve
replacement or reconstruction. Overall, at a mean of 4
years, the SG appears to be safe and has at least comparable,
if not improved, hemodynamic performance.20
In conclusion, our study suggests that the midterm per-
formance of SGs may be superior to that of SCAs. Decellu-
larization of the cryopreserved allografts may provide
a more durable option for patients who need RVOT recon-
struction. Further long-term follow-up is needed to see
whether this decellularization process improves long-term
allograft durability.
A number of important limitations are present in this
analysis. Data were acquired retrospectively and in a non-
randomized manner. The operations were performed by 2
surgeons and the decision for conduit type was determined
by the patient’s anatomy and the conduit’s availability, not
by randomization. Longer follow-up, larger numbers of pa-
tients, matched cohorts, and multicenter prospective studyrdiovascular Surgery c Volume 143, Number 3 547
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cellularized cryopreserved allograft valves in the pulmo-
nary position.References
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Dr James Jaggers (Aurora, Colo). Dr Fortuna and his col-
leagues have presented today a single-institution series of 100 pa-
tients over 7 years that underwent RVOT reconstruction with 39 of
them receiving an SG and 61 receiving an SCA. Importantly,
Dr Fortuna, you have shown that SG valves had superior perfor-
mance with statistically better freedom from conduit failure, con-
duit dysfunction, and conduit replacement at 10 years. This should
be noted to be in contrast with previous experience that showed
a very limited improvement in outcomes with the SG, most of
those related to mild improvement and regurgitation. As you
noted, important limitations of your study and others like this
one regarding its nonrandomized nature, its retrospective nature,
and important differences in the 2 groups leave the audience to
wonder whether these patient groups are really the same. For ex-
ample, there are quite a few more infants receiving smaller allo-
grafts in the SCA group versus the SG group.
I just have 3 brief questions for you. First of all, when you men-
tioned that the echocardiographic analysis was done by a single in-
terpreter, was this interpretation done in a prospective manner or
were these based on previous descriptions in their echocardio-
graphic reports?
Dr Fortuna. Thank you. We obtained the original echocardio-
graphic studies and presented them to a single reviewer in a blinded
fashion. This person reviewed and graded them in a standardized
fashion.
Dr Jaggers. Importantly, did you find any difference when you
analyzed your data between patients who received the orthotopic
versus the heterotopic implant? For example, it is generally recog-
nized that Ross procedure patients have better performance of their
allografts than non-Ross patients. Did you have a chance to look at
your data that way?
Dr Fortuna. I think that is a very good question. It has been
shown at multiple institutions that allografts are more durable
when placed in an orthotopic position versus a heterotopic posi-
tion. In our group we were not able to show any difference.
Dr Jaggers. If you could speculate on the modes of failure, did
you find that the SGs have less calcification? Is there anything that
you can determine that would explain why SGs have improved
performance?
Dr Fortuna. In this retrospective study we did not collect the
tissue samples or systematically study them, but our general im-
pression is that there may be less calcification in the SGs as op-
posed to the SCAs. It is interesting that the function of the valve
seems to be most dramatically affected, and in that case the calci-
fication may play a significant role in the function of those leaflets.
Dr Jaggers. Finally, because these valves are of limited avail-
ability, in your clinical experience, is there a particular patient
group in which you would elect to use an SG versus an SCA?
Dr Fortuna. In our institution our bias is to use the SG in all
patients if we have that opportunity. I think it is a very valid point
that since other studies have shown some risk factors for conduit
failure such as you mentioned, the heterotopic position of the con-
duit, maybe those patients may benefit most from the SG technol-
ogy. We are currently in the process of combining our institution’s
data with those of several other institutions, and our hopes are that
by combining all of that information we will be able to do a more
robust statistical analysis and perhaps do some subgroup analysisery c March 2012
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Das well to provide more information about who would benefit
most.
Dr Jaggers. I enjoyed your paper very much and I think it is go-
ing to be a valuable contribution.
Dr Fortuna. Thank you.
Speaker. I have a question. You are implying that you have 10-
year data, but if I looked at your slides right, at 10 years you had 1
SG patient and 5 SAG patients. Is that correct?
Dr Fortuna. Yes.
Speaker. Do you really consider that to be valid 10-year data.
Dr Fortuna. No, I am not sure that is an entirely valid compar-
ison out at 10 years because of the small numbers, but it does reach
statistical significance. Also, I think you get the sense from looking
at those Kaplan-Meier graphs that there is a divergence in out-
comes between the SGs and the SCAs. Only with longer follow
up will we know whether that maintains statistical significance.The Journal of Thoracic and CaSpeaker. I agree with the early part of your discussion.
Did you make any effort to propensity match these groups, and
don’t you think that would make your data much more believable?
Dr Fortuna. That is a very valid point. We may have been able
to do that. However, we thought there was some value in keeping
a contemporary group for comparison because of other unknown
factors that may affect outcomes. If we did propensity matching
with patients who are taken out of other time periods, for example,
it might be difficult, albeit possible, to take some of those other
factors into consideration. We thought it was best in a single-insti-
tution experiencewith a limited number of patients to take the con-
temporary group in hopes that we are eliminating some of those
other factors.
Speaker. I suggest it may be possible to propensity match even
within your own group, but congratulations on the study.
Dr Fortuna. Thank you.rdiovascular Surgery c Volume 143, Number 3 549
